Literature DB >> 26668321

Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line.

Massimiliano Ruscica1, Chiara Ricci1, Chiara Macchi1, Paolo Magni2, Riccardo Cristofani3, Jingwen Liu4, Alberto Corsini5, Nicola Ferri6.   

Abstract

The suppressor of cytokine signaling (SOCS) proteins are negative regulators of the JAK/STAT pathway activated by proinflammatory cytokines, including the tumor necrosis factor-α (TNF-α). SOCS3 is also implicated in hypertriglyceridemia associated to insulin resistance. Proprotein convertase subtilisin kexin type 9 (PCSK9) levels are frequently found to be positively correlated to insulin resistance and plasma very low density lipoprotein (VLDL) triglycerides concentrations. The present study aimed to investigate the possible role of TNF-α and JAK/STAT pathway on de novo lipogenesis and PCSK9 expression in HepG2 cells. TNF-α induced both SOCS3 and PCSK9 in a concentration-dependent manner. This effect was inhibited by transfection with siRNA anti-STAT3, suggesting the involvement of the JAK/STAT pathway. Retroviral overexpression of SOCS3 in HepG2 cells (HepG2(SOCS3)) strongly inhibited STAT3 phosphorylation and induced PCSK9 mRNA and protein, with no effect on its promoter activity and mRNA stability. Consistently, siRNA anti-SOCS3 reduced PCSK9 mRNA levels, whereas an opposite effect was observed with siRNA anti-STAT3. In addition, HepG2(SOCS3) express higher mRNA levels of key enzymes involved in the de novo lipogenesis, such as fatty-acid synthase, stearoyl-CoA desaturase (SCD)-1, and apoB. These responses were associated with a significant increase of SCD-1 protein, activation of sterol regulatory element-binding protein-1c (SREBP-1), accumulation of cellular triglycerides, and secretion of apoB. HepG2(SOCS3) show lower phosphorylation levels of insulin receptor substrate 1 (IRS-1) Tyr(896) and Akt Ser(473) in response to insulin. Finally, insulin stimulation produced an additive effect with SOCS3 overexpression, further inducing PCSK9, SREBP-1, fatty acid synthase, and apoB mRNA. In conclusion, our data candidate PCSK9 as a gene involved in lipid metabolism regulated by proinflammatory cytokine TNF-α in a SOCS3-dependent manner.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  HepG2; hepatocyte; insulin; proprotein convertase subtilisin/kexin type 9 (PCSK9); stat-3; suppressor of cytokine signaling 3 (SOCS3); tumor necrosis factor (TNF)

Mesh:

Substances:

Year:  2015        PMID: 26668321      PMCID: PMC4751391          DOI: 10.1074/jbc.M115.664706

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

1.  Synthetic peptides containing a conserved sequence motif of the Id protein family modulate vascular smooth muscle cell phenotype.

Authors:  Sara Pellegrino; Nicola Ferri; Noemi Colombo; Edoardo Cremona; Alberto Corsini; Roberto Fanelli; Maria Luisa Gelmi; Chiara Cabrele
Journal:  Bioorg Med Chem Lett       Date:  2009-10-01       Impact factor: 2.823

2.  Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells.

Authors:  Aiqin Cao; Minhao Wu; Hai Li; Jingwen Liu
Journal:  J Lipid Res       Date:  2010-12-31       Impact factor: 5.922

3.  The dual function of hepatic SOCS3 in insulin resistance in vivo.

Authors:  Takehiro Torisu; Naoichi Sato; Daigo Yoshiga; Takashi Kobayashi; Tomoko Yoshioka; Hiroyuki Mori; Mitsuo Iida; Akihiko Yoshimura
Journal:  Genes Cells       Date:  2007-02       Impact factor: 1.891

4.  Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes.

Authors:  Jay D Horton; Nila A Shah; Janet A Warrington; Norma N Anderson; Sahng Wook Park; Michael S Brown; Joseph L Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-25       Impact factor: 11.205

5.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

Authors:  Marianne Abifadel; Mathilde Varret; Jean-Pierre Rabès; Delphine Allard; Khadija Ouguerram; Martine Devillers; Corinne Cruaud; Suzanne Benjannet; Louise Wickham; Danièle Erlich; Aurélie Derré; Ludovic Villéger; Michel Farnier; Isabel Beucler; Eric Bruckert; Jean Chambaz; Bernard Chanu; Jean-Michel Lecerf; Gerald Luc; Philippe Moulin; Jean Weissenbach; Annick Prat; Michel Krempf; Claudine Junien; Nabil G Seidah; Catherine Boileau
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

6.  Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents.

Authors:  Alexis Baass; Geneviève Dubuc; Michel Tremblay; Edgard E Delvin; Jennifer O'Loughlin; Emile Levy; Jean Davignon; Marie Lambert
Journal:  Clin Chem       Date:  2009-07-23       Impact factor: 8.327

7.  Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells.

Authors:  Markey C McNutt; Thomas A Lagace; Jay D Horton
Journal:  J Biol Chem       Date:  2007-05-29       Impact factor: 5.157

8.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance.

Authors:  G S Hotamisligil; N S Shargill; B M Spiegelman
Journal:  Science       Date:  1993-01-01       Impact factor: 47.728

9.  Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor.

Authors:  Hua Sun; Amin Samarghandi; Ningyan Zhang; Zemin Yao; Momiao Xiong; Ba-Bie Teng
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-05-10       Impact factor: 8.311

10.  Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms.

Authors:  Kohjiro Ueki; Tatsuya Kondo; C Ronald Kahn
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

View more
  28 in total

Review 1.  Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.

Authors:  Giuseppe Danilo Norata; Hagai Tavori; Angela Pirillo; Sergio Fazio; Alberico L Catapano
Journal:  Cardiovasc Res       Date:  2016-08-05       Impact factor: 10.787

Review 2.  Lipid testing in infectious diseases: possible role in diagnosis and prognosis.

Authors:  Sebastian Filippas-Ntekouan; Evangelos Liberopoulos; Moses Elisaf
Journal:  Infection       Date:  2017-05-08       Impact factor: 3.553

Review 3.  Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia.

Authors:  Nicola Ferri; Massimiliano Ruscica
Journal:  Endocrine       Date:  2016-04-01       Impact factor: 3.633

4.  Characterization of PCSK9 in the Blood and Skin of Psoriasis.

Authors:  Michael S Garshick; Yvonne Baumer; Amit K Dey; Ryan Grattan; Qimin Ng; Heather L Teague; Zu-Xi Yu; Marcus Y Chen; Michael Tawil; Tessa J Barrett; James Underberg; Edward A Fisher; James Krueger; Tiffany M Powell-Wiley; Martin P Playford; Jeffrey S Berger; Nehal N Mehta
Journal:  J Invest Dermatol       Date:  2020-06-29       Impact factor: 8.551

5.  Enhanced pro-protein convertase subtilisin/kexin type 9 expression by C-reactive protein through p38MAPK-HNF1α pathway in HepG2 cells.

Authors:  Chuan-Jue Cui; Sha Li; Cheng-Gang Zhu; Jing Sun; Ying Du; Yan Zhang; Na-Qiong Wu; Yuan-Lin Guo; Rui-Xia Xu; Ying Gao; Jian-Jun Li
Journal:  J Cell Mol Med       Date:  2016-09-15       Impact factor: 5.310

6.  Proprotein Convertase Subtilisin/Kexin 9 Levels in Relation to Systemic Immune Activation and Subclinical Coronary Plaque in HIV.

Authors:  Markella V Zanni; Lauren A Stone; Mabel Toribio; Dodie E Rimmelin; Jake Robinson; Tricia H Burdo; Kenneth Williams; Kathleen V Fitch; Janet Lo; Steven K Grinspoon
Journal:  Open Forum Infect Dis       Date:  2017-10-14       Impact factor: 3.835

Review 7.  The Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Cardiovascular Homeostasis: A Non-Systematic Literature Review.

Authors:  Ahmad Hachem; Essa Hariri; Perla Saoud; Christelle Lteif; Louis Lteif; Francine Welty
Journal:  Curr Cardiol Rev       Date:  2017

8.  Elevation of serum proprotein convertase subtilisin/kexin type 9 (PCSK9) concentrations and its possible atherogenic role in patients with systemic lupus erythematosus.

Authors:  Chenglong Fang; Tingting Luo; Ling Lin
Journal:  Ann Transl Med       Date:  2018-12

Review 9.  Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis.

Authors:  Emily Punch; Justus Klein; Patrick Diaba-Nuhoho; Henning Morawietz; Mahdi Garelnabi
Journal:  J Am Heart Assoc       Date:  2022-01-20       Impact factor: 6.106

10.  PCSK9 induces a pro-inflammatory response in macrophages.

Authors:  Chiara Ricci; Massimiliano Ruscica; Marina Camera; Laura Rossetti; Chiara Macchi; Alessandra Colciago; Ilaria Zanotti; Maria Giovanna Lupo; Maria Pia Adorni; Arrigo F G Cicero; Federica Fogacci; Alberto Corsini; Nicola Ferri
Journal:  Sci Rep       Date:  2018-02-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.